中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2014年
18期
36-37,38
,共3页
慢性乙型肝炎%肝衰竭%恩替卡韦%拉米夫定
慢性乙型肝炎%肝衰竭%恩替卡韋%拉米伕定
만성을형간염%간쇠갈%은체잡위%랍미부정
Chronic hepatitis B%Liver failure%Cave entecavir%Lamivudine
目的：探讨恩替卡韦治疗慢性乙型肝炎肝衰竭的临床效果。方法：选择笔者所在医院收治的60例慢性乙型肝炎肝衰竭患者，采用随机数字表法将其分为观察组和对照组，各30例。观察组给予恩替卡韦治疗，对照组给予拉米夫定治疗。观察治疗前后两组生化指标(白蛋白、总胆红素、丙氨酸氨基转移酶、凝血酶原活动度)的改变情况及死亡率。结果：观察组治疗3个月后死亡率为3.3%；对照组治疗3个月后死亡率为23.3%。观察组患者治疗期间死亡率低于对照组，差异有统计学意义(P<0.05)。观察组治疗后的白蛋白、总胆红素、丙氨酸氨基转移酶、凝血酶原活动度分别与对照组治疗后比较，差异有统计学意义(P<0.05)。结论：恩替卡韦治疗慢性乙型肝炎肝衰竭近期临床效果显著，值得借鉴。
目的：探討恩替卡韋治療慢性乙型肝炎肝衰竭的臨床效果。方法：選擇筆者所在醫院收治的60例慢性乙型肝炎肝衰竭患者，採用隨機數字錶法將其分為觀察組和對照組，各30例。觀察組給予恩替卡韋治療，對照組給予拉米伕定治療。觀察治療前後兩組生化指標(白蛋白、總膽紅素、丙氨痠氨基轉移酶、凝血酶原活動度)的改變情況及死亡率。結果：觀察組治療3箇月後死亡率為3.3%；對照組治療3箇月後死亡率為23.3%。觀察組患者治療期間死亡率低于對照組，差異有統計學意義(P<0.05)。觀察組治療後的白蛋白、總膽紅素、丙氨痠氨基轉移酶、凝血酶原活動度分彆與對照組治療後比較，差異有統計學意義(P<0.05)。結論：恩替卡韋治療慢性乙型肝炎肝衰竭近期臨床效果顯著，值得藉鑒。
목적：탐토은체잡위치료만성을형간염간쇠갈적림상효과。방법：선택필자소재의원수치적60례만성을형간염간쇠갈환자，채용수궤수자표법장기분위관찰조화대조조，각30례。관찰조급여은체잡위치료，대조조급여랍미부정치료。관찰치료전후량조생화지표(백단백、총담홍소、병안산안기전이매、응혈매원활동도)적개변정황급사망솔。결과：관찰조치료3개월후사망솔위3.3%；대조조치료3개월후사망솔위23.3%。관찰조환자치료기간사망솔저우대조조，차이유통계학의의(P<0.05)。관찰조치료후적백단백、총담홍소、병안산안기전이매、응혈매원활동도분별여대조조치료후비교，차이유통계학의의(P<0.05)。결론：은체잡위치료만성을형간염간쇠갈근기림상효과현저，치득차감。
Objective:To explore the short-term clinical effects of entecavir on hepatic failure in patients with chronic hepatitis B. Method:60 cases of liver failure in patients with chronic hepatitis B were selected in author’s hospital,were randomly divided into observation group and control group,30 cases in each. The observation group was given entecavir,the control group was given lamivudine. The biochemical index(albumin,total bilirubin,alanine aminotransferase, prothrombin activity) were observed before and after treatment in the two groups,the mortality rate was observed in two groups. Result:The death rate in the observation group after treatment of 3 months was 3.3%.The death rate in the control group after treatment of 3 months was 23.3%. The mortality in the observation group patients during treatmentwas lower than that in the control group,the difference was statistically significant(P<0.05). The albumin,total bilirubin,alanine aminotransferase,prothrombin activity in the observation group after treatment compared with those in control group after treatment,the difference was statistically significant(P<0.05). Conclusion:Entecavir on hepatic failure in patients with chronic hepatitis B has significant efficacy,and the therapy is worthy of reference.
